Landos Biopharma Announces Positive Results from a Phase 2 Trial of Oral BT-11 for Patients with Ulcerative Colitis
-Once a day oral dosing with BT-11 induced placebo-adjusted clinical remission rates of up to 11.5% at week 12- -A small subset of biologic-experienced patients also showed positive trends in clinical remission rates- -Normalization of biomarkers such as …